Grifols, S.A. (GIFLF)

Market Cap	7.07B
Revenue (ttm)	7.97B
Net Income (ttm)	211.01M
Shares Out	n/a
EPS (ttm)	0.31
PE Ratio	33.53
Forward PE	10.51
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,000
Average Volume	221
Open	10.95
Previous Close	10.45
Day's Range	10.95 - 10.95
52-Week Range	8.40 - 11.39
Beta	0.93
RSI	91.90
Earnings Date	Jul 25, 2025

About Grifols

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma, and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factor VIII/von Willebrand factor and factor IX, clotting factors for the treatment of hemophilia A an...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 23,833
• Stock Exchange: OTCMKTS
• Ticker Symbol: GIFLF

Financial Performance

In 2024, Grifols's revenue was 7.21 billion, an increase of 9.41% compared to the previous year's 6.59 billion. Earnings were 156.92 million, an increase of 270.81%.

Financial numbers in EUR